Lindsay R, Pack S, Li Z. Longitudinal Progression of Fracture Prevalence through a Population of Postmenopausal Women with Osteoporosis. Osteoporos Int. 2005; 16(3): 306-12. http://www.ncbi.nlm.nih.gov/pubmed/15455193
A systematic review of osteoporosis therapies found good evidence that many are effective in preventing fractures, but concluded that the data are insufficient to determine if any one therapy is… [ Get More Details ]
Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.
[ Get More Details ]
Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by… [ Get More Details ]